Aarkstore - Primary Biliary Cirrhosis - Pipeline Review, H2 2014

1
Primary Biliary Cirrhosis - Pipeline Review, H2
2014
Pharmaceutical and Healthcare Market Research
Report
2
Summary

• Primary Biliary Cirrhosis - Pipeline Review, H2
  2014, provides an overview of the Primary Biliary
  Cirrhosiss therapeutic pipeline.
• This report provides comprehensive information
  on the therapeutic development for Primary
  Biliary Cirrhosis, complete with comparative
  analysis at various stages, therapeutics
  assessment by drug target, mechanism of action
  (MoA), route of administration (RoA) and molecule
  type, along with latest updates, and featured
  news and press releases. It also reviews key
  players involved in the therapeutic development
  for Primary Biliary Cirrhosis and special
  features on late-stage and discontinued
  projects.Global Markets Directs report features
  investigational drugs from across globe covering
  over 20 therapy areas and nearly 3,000
  indications. The report is built using data and
  information sourced from Global Markets Directs
  proprietary databases, Company/University
  websites, SEC filings, investor presentations and
  featured press releases from company/university
  sites and industry-specific third party sources,
  put together by Global Markets Directs team. Drug
  profiles/records featured in the report undergoes
  periodic updation following a stringent set of
  processes that ensures that all the profiles are
  updated with the latest set of information.

3
Scope

• The report provides a snapshot of the global
  therapeutic landscape of Primary Biliary
  Cirrhosis- The report reviews key pipeline
  products under drug profile section which
  includes, product description, MoA and RD brief,
  licensing and collaboration details other
  developmental activities - The report reviews
  key players involved in the therapeutics
  development for Primary Biliary Cirrhosis and
  enlists all their major and minor projects- The
  report summarizes all the dormant and
  discontinued pipeline projects - A review of the
  Primary Biliary Cirrhosis products under
  development by companies and universities/research
  institutes based on information derived from
  company and industry-specific sources- Pipeline
  products coverage based on various stages of
  development ranging from pre-registration till
  discovery and undisclosed stages- A detailed
  assessment of monotherapy and combination therapy
  pipeline projects
• - Coverage of the Primary Biliary Cirrhosis
  pipeline on the basis of target, MoA, route of
  administration and molecule type- Latest news
  and deals relating related to pipeline products

4
Reasons to buy

• - Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies- Identify
  emerging players with potentially strong product
  portfolio and create effective counter-strategies
  to gain competitive advantage- Develop strategic
  initiatives by understanding the focus areas of
  leading companies- Identify and understand
  important and diverse types of therapeutics under
  development for Primary Biliary Cirrhosis- Plan
  mergers and acquisitions effectively by
  identifying key players of the most promising
  pipeline- Devise corrective measures for
  pipeline projects by understanding Primary
  Biliary Cirrhosis pipeline depth and focus of
  Indication therapeutics- Develop and design
  in-licensing and out-licensing strategies by
  identifying prospective partners with the most
  attractive projects to enhance and expand
  business potential and Scope- Modify the
  therapeutic portfolio by identifying discontinued
  projects and understanding the factors that drove
  them from pipeline

5
Table of Content

• Global Markets Direct Report Coverage 6Primary
  Biliary Cirrhosis Overview 7Therapeutics
  Development 8Pipeline Products for Primary
  Biliary Cirrhosis - Overview 8Pipeline Products
  for Primary Biliary Cirrhosis - Comparative
  Analysis 9Primary Biliary Cirrhosis -
  Therapeutics under Development by Companies
  10Primary Biliary Cirrhosis - Pipeline Products
  Glance 12Late Stage Products 12Clinical Stage
  Products 13Early Stage Products 14Primary
  Biliary Cirrhosis - Products under Development by
  Companies 15Primary Biliary Cirrhosis -
  Companies Involved in Therapeutics Development
  16AlbireoPharma 16Dr. Falk Pharma GmbH
  17GlaxoSmithKline plc 18Intercept
  Pharmaceuticals, Inc. 19Johnson Johnson 20

6
List of Tables

• Number of Products under Development for Primary
  Biliary Cirrhosis, H2 2014 8Number of Products
  under Development for Primary Biliary Cirrhosis -
  Comparative Analysis, H2 2014 9Number of
  Products under Development by Companies, H2 2014
  11Comparative Analysis by Late Stage
  Development, H2 2014 12Comparative Analysis by
  Clinical Stage Development, H2 2014
  13Comparative Analysis by Early Stage
  Development, H2 2014 14Products under
  Development by Companies, H2 2014 15Primary
  Biliary Cirrhosis - Pipeline by AlbireoPharma, H2
  2014 16Primary Biliary Cirrhosis - Pipeline by
  Dr. Falk Pharma GmbH, H2 2014 17Primary Biliary
  Cirrhosis - Pipeline by GlaxoSmithKline plc, H2
  2014 18Primary Biliary Cirrhosis - Pipeline by
  Intercept Pharmaceuticals, Inc., H2 2014
  19Primary Biliary Cirrhosis - Pipeline by
  Johnson Johnson, H2 2014 20Primary Biliary
  Cirrhosis - Pipeline by MediGene AG, H2 2014
  21Primary Biliary Cirrhosis - Pipeline by NGM
  Biopharmaceuticals, Inc., H2 2014 22Primary
  Biliary Cirrhosis - Pipeline by Shire Plc, H2
  2014 23Primary Biliary Cirrhosis - Pipeline by
  Virobay Inc., H2 2014 24

7
List of Figures

• Number of Products under Development for Primary
  Biliary Cirrhosis, H2 2014 8Number of Products
  under Development for Primary Biliary Cirrhosis -
  Comparative Analysis, H2 2014 9Number of
  Products under Development by Companies, H2 2014
  10Comparative Analysis by Clinical Stage
  Development, H2 2014 13Assessment by Monotherapy
  Products, H2 2014 25Number of Products by Top 10
  Targets, H2 2014 26Number of Products by Stage
  and Top 10 Targets, H2 2014 27Number of Products
  by Top 10 Mechanism of Actions, H2 2014 28Number
  of Products by Stage and Top 10 Mechanism of
  Actions, H2 2014 29Number of Products by Top 10
  Routes of Administration, H2 2014 30Number of
  Products by Stage and Top 10 Routes of
  Administration, H2 2014 31Number of Products by
  Top 10 Molecule Types, H2 2014 32Number of
  Products by Stage and Top 10 Molecule Types, H2
  2014 33

8
Related Reports

• Fabry Disease-Pipeline Insights, 2015
• Ocular Hypertension-Pipeline Insights, 2015
• Fallopian Tube Cancer-Pipeline Insights, 2015
• Ocular Inflammation-Pipeline Insights, 2015
• Familial Adenomatous Polyposis Coli-Pipeline
  Insights, 2015
• Ocular Pain-Pipeline Insights, 2015
• Oligodendroglioma-Pipeline Insights, 2015
• Familial Chylomicronemia (Type I
  Hyperlipoproteinemia)-Pipeline Insights, 2015

9
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953